WHO ICTRP trial
C-reactive protein response to newborn hepatitis B immunisation
ACTRN12611000043932 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12611000043932 |
|---|---|
| Public title | C-reactive protein response to newborn hepatitis B immunisation |
| Scientific title | C-reactive protein response to newborn hepatitis B immunisation |
| Primary sponsor | Scott Morris |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | Australia |
| Conditions | Concentration of C-reactive protein in blood after hepatitis B immunisation; Concentration of C-reactive protein in blood after hepatitis B immunisation;Inflammatory and Immune System - Normal development and function of the immune system |
| Interventions | Term babies born by elective caesarean section are randomised to recieve routine intramuscular monovalent hepatitis B immunisation (0.5mL of H-B-Vax II, CSL Biotherapies/Merck & Co Inc, containing 5 micrograms of hepatitis B surface antigen… |
| Registration date | Jan 13, 2011 |
| Target size | 42 |
| Secondary IDs | Nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: